Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, November 8 '25)

Image
By G.M.

 


    Acad Emerg Med

  1. OHLE R, Roy D, Baraku E, Patel K, et al
    A Prospective Multi-Center Implementation Study to Improve the Diagnosis and Treatment of Benign Paroxysmal Positional Vertigo.
    Acad Emerg Med. 2025 Nov 3. doi: 10.1111/acem.70177.
    PubMed         Abstract available


    Am J Obstet Gynecol

  2. YE Y, Mahati S, Aihemaiti W, Lu G, et al
    A postpartum-adapted algorithm for safe management of suspected pulmonary embolism: a retrospective cohort study.
    Am J Obstet Gynecol. 2025 Nov 1:S0002-9378(25)00813.
    PubMed         Abstract available


    Antiviral Res

  3. DENG X, Zou J, Liang Z, Ren P, et al
    A Dual-Reporter HCoV-OC43 for Coronavirus Biology and Countermeasure Development.
    Antiviral Res. 2025 Nov 3:106306. doi: 10.1016/j.antiviral.2025.106306.
    PubMed         Abstract available


    BMJ

  4. WISE J
    Covid-19: Major study compares myocarditis risk in children after vaccination or infection.
    BMJ. 2025;391:r2330.
    PubMed        

  5. OLIVAR JMN, da Silva Costa E, Putira Sacuena ER
    Indigenous women's leadership in the Amazon: how lessons learned from covid-19 can strengthen our response to the climate crisis.
    BMJ. 2025;391:r2139.
    PubMed        


    Clin Infect Dis

  6. KURIAKOSE S, Tseng A, Boyd S, Gibbons S, et al
    International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness.
    Clin Infect Dis. 2025 Nov 3:ciaf606. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  7. HONG Y, Zhu F, Chen Y, Liu Y, et al
    Competitive Dynamics of ST764 and ST5 MRSA in a New Tertiary ICU: Enhanced Hospital Adaptation via agrC Mutations Post-COVID-19.
    Int J Infect Dis. 2025 Nov 4:108186. doi: 10.1016/j.ijid.2025.108186.
    PubMed         Abstract available

  8. CREUS-COSTA A, Andres C, Vila J, Gonzalez-Sanchez A, et al
    Decline in pediatric respiratory syncytial virus hospitalizations following nirsevimab implementation: a multicenter, three-season observational study.
    Int J Infect Dis. 2025 Oct 31:108170. doi: 10.1016/j.ijid.2025.108170.
    PubMed         Abstract available

  9. LAU JC, Cheung KW, Yu Q, Wu P, et al
    Disease Pattern, Risk factors of Antimicrobial Resistance in Patients with Pneumococcal Infection in Hong Kong Population.
    Int J Infect Dis. 2025 Oct 30:108174. doi: 10.1016/j.ijid.2025.108174.
    PubMed         Abstract available


    J Med Virol

  10. SILVA AEF, Costa PT, Mello LS, Marques LFA, et al
    Characterization of the Epidemiological Profile of Patients With Parkinson's Disease Who Were Hospitalized due to SARS-CoV-2 Infection: A Portrait of 4 Years of the Pandemic in Brazil.
    J Med Virol. 2025;97:e70670.
    PubMed         Abstract available

  11. SHI TH, Kuo C, Lin YT, Liu YC, et al
    Moringin as a Lead Compound for Anti-Enteroviruses and Coronaviruses Broad-Spectrum Inhibition of Viral Proteases: Comparative Evaluation With Glucomoringin and Antiviral Agents.
    J Med Virol. 2025;97:e70665.
    PubMed         Abstract available


    J Virol

  12. ZHAO M, Zhang Y, Liang Y, Lei F, et al
    SARS-CoV-2 polyprotein expression and the induction of double-membrane vesicles.
    J Virol. 2025 Nov 6:e0138525. doi: 10.1128/jvi.01385.
    PubMed         Abstract available

  13. POWERS JM, Leist SR, Suryadevara N, Zost SJ, et al
    Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice.
    J Virol. 2025 Nov 6:e0140625. doi: 10.1128/jvi.01406.
    PubMed         Abstract available

  14. IRELAND J, Myers D, Huang C, Allen C, et al
    Vaccination protects against COVID-associated pulmonary fibrin deposition.
    J Virol. 2025 Nov 6:e0063325. doi: 10.1128/jvi.00633.
    PubMed         Abstract available

  15. WANG C, Shuai L, Zhong G, Wen Z, et al
    Transmission of SARS-CoV-2 between ferrets in presence of pre-existing immunity.
    J Virol. 2025 Nov 4:e0156625. doi: 10.1128/jvi.01566.
    PubMed         Abstract available


    JAMA

  16. PANT S
    New COVID-19 Vaccination Guidelines for Immunocompromised Individuals.
    JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19727.
    PubMed        


    Lancet

  17. MAYER KH, Beyrer C, Cohen MS, El-Sadr WM, et al
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet. 2025;406:2168-2190.
    PubMed         Abstract available


    Nature

  18. DE MAIO N, Ly-Trong N, Martin S, Minh BQ, et al
    Assessing phylogenetic confidence at pandemic scales.
    Nature. 2025 Nov 5. doi: 10.1038/s41586-025-09567.
    PubMed         Abstract available

  19. KAVANAGH K
    COVID-19 is spreading again - how serious is it and what are the symptoms?
    Nature. 2025 Nov 4. doi: 10.1038/d41586-025-03412.
    PubMed  
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »